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Abstract
Background: The identification of patients with advanced liver fibrosis secondary to non-alcoholic fatty liver
disease (NAFLD) remains challenging. Using non-invasive liver fibrosis tests (NILT) in primary care may permit earlier
detection of patients with clinically significant disease for specialist review, and reduce unnecessary referral of
patients with mild disease. We constructed an analytical model to assess the clinical and cost differentials of such
strategies.
Methods: A probabilistic decisional model simulated a cohort of 1000 NAFLD patients over 1 year from a
healthcare payer perspective. Simulations compared standard care (SC) (scenario 1) to: Scenario 2: FIB-4 for all
patients followed by Enhanced Liver Fibrosis (ELF) test for patients with indeterminate FIB-4 results; Scenario 3: FIB-4
followed by fibroscan for indeterminate FIB-4; Scenario 4: ELF alone; and Scenario 5: fibroscan alone. Model
estimates were derived from the published literature. The primary outcome was cost per case of advanced fibrosis
detected.
Results: Introduction of NILT increased detection of advanced fibrosis over 1 year by 114, 118, 129 and 137%
compared to SC in scenarios 2, 3, 4 and 5 respectively with reduction in unnecessary referrals by 85, 78, 71 and 42%
respectively.
The cost per case of advanced fibrosis (METAVIR ≥F3) detected was £25,543, £8932, £9083, £9487 and £10,351 in
scenarios 1, 2, 3, 4 and 5 respectively. Total budget spend was reduced by 25.2, 22.7, 15.1 and 4.0% in Scenarios 2,
3, 4 and 5 compared to £670 K at baseline.
Conclusion: Our analyses suggest that the use of NILT in primary care can increases early detection of advanced
liver fibrosis and reduce unnecessary referral of patients with mild disease and is cost efficient. Adopting a two-tier
approach improves resource utilization.
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Background
The health, societal and economic burden of chronic liver
disease (CLD) is substantial and represents a public health
priority [1, 2]. CLD is the 5th commonest cause of death
in the United Kingdom, and the only one in the top five
that is increasing [3]. With rising prevalence of risk factors
for liver disease including obesity and alcohol, pressure on
healthcare resources is likely to intensify. Better and earl-
ier detection of CLD in primary care is key to improving
health outcomes and associated costs [4].
Non alcoholic fatty liver disease (NAFLD) is the com-
monest cause of deranged liver function tests (LFTs) in
primary care [5]. Only a minority (5%) of these cases pro-
gresses to clinically significant liver disease [6] whilst evi-
dence highlights fibrosis severity as the key determinant of
liver related morbidity and mortality [7, 8]. The identifica-
tion of patients with significant liver disease is a primary
care challenge, where accurate fibrosis assessment is
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limited by a reliance on LFTs, which are poor discrimina-
tors of liver fibrosis [9].
In the current ‘standard care’ (SC), primary care
physicians (PCP) assess the severity of a patient’s liver
disease and subsequent need for specialist referral
based on history, examination, blood tests including
LFTs and ultrasound.
Patients referred to secondary care deemed to have sig-
nificant liver disease due to NAFLD may benefit from ac-
tive management (including consideration for clinical
trials of emerging therapies for NAFLD and fibrosis) [2,
10]. Patients with cirrhosis will be enrolled in pathways of
care that improve outcomes through targeted screening
and treatment for complications of cirrhosis including
portal hypertension [11] and hepatocellular carcinoma
(HCC) [12]. However, current primary care approaches re-
sult in the referral of many patients that do not have sig-
nificant liver fibrosis, placing a burden on secondary care
services, incurring unwarranted costs and generating un-
necessary inconvenience and anxiety for patients [13].
Furthermore a significant number of patients with ad-
vanced liver fibrosis are missed and not referred to sec-
ondary care. These patients have been falsely reassured
and will silently progress before presenting with end-stage
liver disease or liver cancer.
The use of non-invasive liver fibrosis tests (NILT) [14]
may improve PCP staging of disease [4, 15] and referral
practice but there is a lack of health-economic evidence
about the use of NILT in fatty liver disease to inform cli-
nicians, commissioners and policy makers about the
value of such strategies. In this study, we developed a
probabilistic decision analytical model to investigate the
clinical and cost impact of primary care risk stratifica-
tion of patients with NAFLD.
Methods
A liver working group, comprising primary care physicians
and secondary care liver specialists, commissioners, public
health practitioners and patient representatives was
formed in the London Boroughs of Camden and Islington
to develop new pathways of care for patients with NAFLD.
Part of the strategy was to establish current practice
(standard care (SC)) (Fig. 1) and to establish pragmatic
guidance on how to improve the identification of NAFLD
cases with advanced liver disease for referral to secondary
care. In the first instance, PCP favoured the selection of
patients with deranged liver function tests (LFT) even
though it was agreed that this would miss a minority of
cases with liver fibrosis who have normal LFTs.
Probabilistic decision model
A probabilistic decision analytical simulation model was
created using Microsoft Excel Software (version16.23,
2019). The model piloted competing primary care risk
stratification diagnostic strategies for 1000 patients with
a confirmed diagnosis of NAFLD (Fig. 2). The average
patient was 50 years old with elevated transaminases.
The cycle length was 1 year.
Competing Strategies in the Model and Analyses
We modelled the standard care in the UK National Health
Service (NHS) (scenario 1). The use of FIB-4 and ELF in a
two-tier stratification approach (scenario 2) was modelled
to replicate a local pilot pathway - the Camden and Isling-
ton NAFLD pathway [13]. Following an independent evalu-
ation of NILT public health consultants favoured the use of
FIB-4 over the NAFLD Fibrosis Score, in part due to a lack
of standardization in the diagnosis of diabetes. Fibroscan is
increasingly established in secondary care practice, and was
incorporated to assess its performance in place of ELF in a
two-tier strategy (Scenario 3). One-tier approaches were
also considered in which SC was supported by ELF (sce-
nario 4), or fibroscan alone (Scenario 5).
In all scenarios SC delivered by PCPs included history,
physical assessment followed by investigation of liver
function, tests for viral, immune and metabolic causes of
liver disease and an ultrasound scan in order to make an
assessment of the risk of advanced liver fibrosis. This was
classified as a binary outcome with the case deemed to be
at ‘high risk’ of advanced liver disease necessitating refer-
ral to a specialist, or at ‘low risk’ and thus appropriate for
management in primary care. This decision process re-
quired 3 PCP consultations, 3 routine bloods tests and 1
ultrasound scan. In scenarios 2 and 3, SC was supported
by the calculation of a FIB-4 score in all patients to im-
prove the identification of patients at risk of advanced fi-
brosis (METAVIR ≥ F3). Low risk patients (FIB-4 < 1.30)
were managed in primary care whilst high-risk patients
(FIB-4 > 3.25) were referred to a specialist in secondary
care. Patients with indeterminate scores (FIB-4 1.30–3.25)
required an ELF test (Scenario 2) or a community fibros-
can (Scenario 3). Published cut-offs were used to identify
cases at increased risk of advanced fibrosis (≥10.3 for ELF
and ≥ 7.9 kPa for Fibroscan). A fibroscan failure rate of 5%
was assumed [47]. For patients managed in Scenario 4, SC
was followed by ELF test for all patients and in Scenario 5
SC was followed by fibroscan for all patients.
Patients identified as being at high-risk of advanced fibro-
sis were referred to a secondary care specialist. Evaluation
included further blood tests, fibroscan, imaging including
US scan (50% of cases, informed by local audit), CT scan
(5% of cases, informed by local audit), MRI Liver (5%, in-
formed by local audit) and liver biopsy (15% of cases, in-
formed by local audit). Patients deemed to not have
advanced fibrosis (false positive) would be discharged to
primary care, whilst those confirmed with advanced fibrosis
would enter recognised surveillance pathways.
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The time horizon for the base-case was 1 year to assess
short-term benefits, likely to relate to resource utilisa-
tion. A 5- year timeframe was applied to assess the
longer-term implications.
Clinical data inputs
A comprehensive literature search informed model pa-
rameters. The data were critically assessed to ensure
suitability for this study and were supplemented by ex-
pert opinion when required.
The model assumed an intention-to-diagnose strategy.
All patients would be managed according to the path-
ways. SC performance is poorly documented, but esti-
mates were extrapolated from available studies [13, 16,
17]. Advanced fibrosis (≥F3 fibrosis) prevalence was set
at 7.5% [5] and published sensitivities and specificities of
FIB-4 [18, 19], ELF [19, 20] and fibroscan [19, 21] were
used to predict stratification rates for low- and high- risk
of advanced fibrosis (Table 1 and Fig. 3). Estimates of
NAFLD disease progression were used to inform path-
way performance (Table 2).
Fig. 1 Schematic simulating current ‘standard of care’ patient journey. Simplified simulated journey of a patient with NAFLD through the
healthcare system after primary care assessment using standard of care over a 1-year timeframe (see Table 1 and Table 2 for references). The
diagnostic performance of the primary care assessment has four outcomes - 1) ‘True positive’; Patients deemed to be at high risk for advanced
fibrosis subsequently confirmed as having≥ F3 fibrosis after specialist assessment. Patients will be actively managed in secondary care (including
consideration for clinical trials). Patients with cirrhosis will be enrolled in pathways of care that improve outcomes through targeted screening
and treatment for portal hypertension and hepatocellular carcinoma (HCC). 2) ‘True negative’; Patients deemed to be at low risk for advanced fibrosis
found to have≤ F2 disease. These patients are unlikely to suffer morbidity from their liver disease. Management in primary care should be
focussed on managing reversible metabolic disorders. 3) ‘False positive’; Patients deemed to be at high risk for advanced fibrosis in primary care but
found to have≤ F2 fibrosis. The pathway can be considered to have failed this group of patients, whom can be managed effectively in primary
care with weight loss and exercise. 4) ‘False negative’; Patients deemed to be at low risk for advanced fibrosis who have≥ F3 fibrosis. This cohort of
patients have been falsely reassured and represent a failure of the pathway as they remain in primary care unless they present with complications
of CLD if their disease progresses, at which point interventions are increasingly limited
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Cost data inputs
A healthcare payer perspective was adopted. Costs were de-
rived from published resources and local costing tariffs
(February 2015) (Table 3) for the UK. A 3.5% discount rate
was applied. Direct healthcare costs included PCP consulta-
tions, blood tests and ultrasound scans. The cost of FIB-4
was considered to be £0, as ALT, AST and platelet tests
were incorporated as ‘routine blood tests’. ELF was priced
at £42, the quoted rate charged to the Camden and Isling-
ton CCG in their pathway, and fibroscan was priced at £43
[19]. In secondary care, the costs incurred related to spe-
cialist consultations, investigations including liver biopsy
Fig. 2 Decision tree presenting overview of transition of a patient with NAFLD through the model. In the model, a patient with NAFLD and≤ F2
fibrosis could remain well, progress to F3 fibrosis or die. A patient with F3 fibrosis could remain well, progress to compensated cirrhosis, develop
HCC or die. Patients with compensated cirrhosis could remain stable, develop a complication of cirrhosis, undergo liver transplantation or die. The
model differentiated early stage complications (non-bleeding varices detected by surveillance endoscopy, Barcelona Clinic Liver Cancer (BCLC)
stage 0/A HCC and mild/moderate ‘other’ complication including ascites, jaundice and hepatic encephalopathy managed as outpatient), from
late stage complications (bleeding varices, BCLC stage B-D HCC and severe ‘other’ CLD complications necessitating inpatient admission)
Table 1 Test performance and Disease prevalence estimates
Test characteristics Sensitivity Specificity Reference
Standard of care 0.35 0.65 Expert Opinion [16, 17]
FIB-4 (cut off 1.30) 0.84 0.74 [18, 19]
FIB-4 (cut off 3.25) 0.38 0.97 [18, 19]
ELF 0.80 0.90 [19, 20]
Fibroscan 0.82 0.84 [19, 21]
Population and disease characteristics Transition probability
Prevalence of advanced fibrosis in the general population 0.075 [5]
Published test characteristics of non-invasive liver fibrosis tests to detect advanced fibrosis (METAVIR ≥F3) in patients with non-alcoholic fatty liver disease
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and expenditure related to HCC surveillance (6 monthly
AFP and ultrasound) and variceal surveillance (2–3 yearly
endoscopy). Finally, costs for the management of complica-
tions of CLD, including inpatient and outpatient costs,
pharmacological treatment and surgical procedures includ-
ing liver resection and transplant were obtained from the
Royal Free London NHS Foundation Trust finance
department.
The primary outcome measure was cost per case of ad-
vanced fibrosis detected - a surrogate for cost utility.
Secondary outcomes included unnecessary referral rates
of patients with non-advanced disease, the severity of CLD
complications, liver transplantation and mortality rates.
Results
Clinical outcome
The base case analysis for 1000 patients with NAFLD
over a 1-year timeframe demonstrated 650 patients
(65%) were identified as being at low risk of advanced fi-
brosis and remained in primary care (scenario 1, SC). Of
this group, 49 patients (8%) had advanced fibrosis but
remained in primary care inappropriately (false negative
rate). The remaining 350 patients (35%) were referred to
a specialist. After specialist investigation, 93% (324 pa-
tients) were determined to be at low risk (false positive
rate) and discharged whilst 26 patients (7%) were con-
firmed to have advanced fibrosis (true positive) and pro-
gressed on specialist pathways.
The impact of introducing non-invasive tests into pri-
mary care using FIB-4 and ELF (Scenario 2), FIB-4 and
TE (Scenario 3), ELF alone (scenario 4) or TE alone
(Scenario 5) was assessed (Fig. 4 and Table 4). Over the
1 year time-horizon, compared to SC these strategies re-
duced the relative referral rate from primary care to hos-
pital by 70, 67, 56 and 43% for scenarios 2, 3, 4 and 5
respectively; corresponding to 245, 223, 198 and 150
fewer referrals over 1 year per 1000 patients. This re-
duced the need for investigation performed in secondary
care. The number of patients requiring imaging in sec-
ondary care reduced by 147, 134, 118 and 60 in
Fig. 3 Flow diagram depicting patient flow in each simulated scenario. Published test performances allowed prediction of true and false positive
and negative rates for detection of advanced fibrosis (≥F3) in each scenario
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Table 2 Transitional probability estimates used to populate the probabilistic analytical model for the base case (annual progression
rates)
Parameter/ Health state Transition probability References
Population and disease characteristics
Prevalence of advanced fibrosis in the general population 0.075 [5]
Reduction in fibrosis progression after GP management 0.01 [22], Author assumption
Reduction in fibrosis progression after specialist review 0.025 [22]
Mild/ No fibrosis (F0, F1, F2)
Remain healthy 0.99 [23–26]
Develop F3 disease 0.001 [23, 24]
Mortality (all cause) 0.005 [25, 27, 28]
Discharge from specialist services 0.7 Unpublished audit
Advanced fibrosis (F3)
Remain healthy 0.95 [25, 29, 30]
Develop F4 disease/ cirrhosis 0.04 [25, 29, 30]
Develop HCC (without cirrhosis) 0.004 [29]
Mortality (all cause) 0.005 [29]
Compensated cirrhosis (F4)
Remain compensated 0.93 Calculated from other variables
Develop varices 0.03 [31]
Develop HCC 0.003 [32, 34–37]
Develop other complications (inc. jaundice, ascites, HE) 0.02 [29, 31, 32]
Mortality (all cause) 0.02 [31, 38, 39], expert opinion
BCLC Stage 0 and A HCC
Cure (liver transplant) 0.36 [40]
Cure (non transplant) 0.39 [40]
Mortality (all cause) 0.25 [40]
BCLC stage B – D HCC
Clinical stability (post TACE, RFA etc) 0.24 [41]
Mortality (all cause) 0.76 [35]
Varices detection in surveillance programme
Clinical stability 0.92 [42]
Liver transplant 0.01 Expert opinion
Mortality (all cause) 0.07 [33]
Detection of varices after emergency presentation
Clinical stability 0.73 [43]
Liver transplant 0.02 [42]
Mortality (all cause) 0.25 [44]
Mild/ Moderate ‘other’ complication
Clinical stability 0.74 [17]
Liver transplant 0.10 [42]
Mortality (all cause) 0.16 [17]
Severe ‘other’ complication
Clinical stability 0.45 [17]
Liver transplant 0.10 [42]
Mortality (all cause) 0.45 [17]
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scenarios 2, 3, 4, and 5 respectively, whilst 25, 22, 20 and
10 fewer patients required endoscopy after 1 year per
1000 patients referred. The requirement for liver biopsy
was reduced by 37, 33, 30 and 15 patients in scenarios 2,
3, 4 and 5 respectively. This translated into cost savings in
secondary care investigation in the first year per 1000 pa-
tients referred of £165,530.04, £150,184.67, £133,505.60
and £68,256.85 for scenarios 2, 3, 4 and 5 respectively.
These approaches resulted in reductions in referral of
patients with non-advanced liver fibrosis (deemed “un-
necessary” referrals) by 85, 78, 71 and 42% (absolute re-
duction) in scenarios 2, 3, 4, and 5 respectively
compared to scenario 1; corresponding to 275, 253, 231
and 137 reduction in inappropriate referrals from 324
patients in scenario 1 over the 1-year time horizon.
TE alone was the most clinically effective strategy in
the detection of ≥F3 fibrosis. Compared to SC, introdu-
cing NILT increased the identification of patients with
advanced fibrosis (true positive rate) by 30, 31, 34 and
36 patients in scenarios 2, 3, 4 and 5 respectively equat-
ing to an 114, 118, 129 and 137% improvement..
Considering cirrhosis specifically, over the 1-year time-
frame, employing each of the strategies improved detec-
tion by 1 patient per 1000 population compared to the
SC,. Specifically, an extra 1.2 (113%), 1.2 (116%), 1.3
(128%) and 1.4 (136%) cirrhotic patients per 1000
Table 2 Transitional probability estimates used to populate the probabilistic analytical model for the base case (annual progression
rates) (Continued)
Parameter/ Health state Transition probability References
Severity of CLD Complication No screening Screening
Probability of BCLC stage 0 + A HCC 0.299 0.709 [45]
Probability of BCLC stage B - D HCC 0.701 0.291 [45]
Detecting varices in surveillance programme 0.0 0.60 [42]
Detecting varices after emergency presentation 100.0 0.40 [42]
Mild/ moderate CLD ‘other’ complication 0.527 0.622 [17, 46]
Severe CLD ‘other’ complication 0.473 0.378 [17, 46]
Table 3 Health care costs for patients with NAFLD/ NASH (£, 2014–2015)
Resource Use Unit Cost Reference
Primary Care
GP consultation (per patient contact lasting 11.7 min) £45.00 [48]
Secondary care
Hepatology Consultant appointment (new) £148.34 Royal Free, February 2015
Hepatology Consultant follow up appt £98.63 Royal Free, February 2015
Dietician review £57.00 Royal Free, February 2015
Investigations
Routine blood tests (inc. FBC, LFT’s, INR) £68.06 Royal Free, February 2015
Liver aetiology panel £147.98 Royal Free, February 2015
FIB-4 (AST/ALT/ platelets included in ‘routine blood tests’) £0.00 Royal Free, February 2015
ELF £42.00 North Middlesex Hospital, February 2015,
Ultrasound Liver £63.67 Royal Free, February 2015
CT Abdomen/ Liver £80.78 Royal Free, February 2015
MRI Abdomen/ Liver £101.00 Royal Free, February 2015
Fibroscan £43.00 Royal Free, February 2015
Liver biopsy £642.75 Royal Free, February 2015
Endoscopy £264.00 Royal Free, February 2015
Surgical procedures
Liver resection £7000 [49]
Liver transplant (1st year) £70,000 [19, 49, 50], Royal Free, February 2015
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population were detected in scenarios 2, 3, 4 and 5 re-
spectively over 1 year compared to SC.
The model tested the impact of earlier detection of ad-
vanced fibrosis on complications of CLD (Table 4). Patients
known to have cirrhosis routinely undergo regular surveil-
lance. The model demonstrated that the number of patients
presenting with curable HCC (Stage O/A) increased from a
base case of 0.17 patients per 1000 population following
SC, by 0.06 patients per 1000 population in scenarios 2 and
3 and by 0.07 and 0.08 patients per 1000 population in sce-
narios 4 and 5 respectively. Conversely, over 1 year, incur-
able HCC (stage B-D), rates decreased from a base case of
0.22 patients per 1000 population following SC the same
amounts equivalent to reductions of 29, 30, 33 and 35% for
scenarios 2–5 respectively. Patients presenting with variceal
haemorrhage reduced by 0.02 patients per 1000 population
in scenarios 2, 3 and 4, and by 0.03 patients per 1000 popu-
lation in scenario 5, compared to SOC (0.07 patients per
1000 population). The model predicted that variceal detec-
tion through surveillance prior to haemorrhage increased
from 0.02 patients per 1000 with SC by 0.02 patients per
1000 in scenarios 2, 3, 4 and 0.03 patients per 1000 in sce-
nario 5, permitting the instigation of primary prophylaxis of
variceal haemorrhage that is associated with reduced mor-
tality [44]. Finally, the model demonstrated that manage-
ment of cirrhosis in secondary care achieved a reduction in
episodes of hospitalization due to other complications of
CLD including jaundice, ascites and hepatic encephalop-
athy from 0.03 patients per 1000 in SC by 0.01 patients per
1000 in all scenarios.
Improvements in the detection and management of cir-
rhosis would permit increased rates of liver transplantation
by 0.02 patients per 1000 in scenarios 2 and 3 and 0.03 pa-
tients per 1000 in scenarios 4 and 5, compared to SC (0.07
patients per 1000) over 1 year. Predicted all-cause mortality
reduced by 0.03 patients per 1000 in scenarios 2 and 3 and
0.04 patients per 1000 in scenarios 4 and 5 over 1 year
compared to SC (9.87 patients per 1000).
Cost outcome
The healthcare costs of the competing strategies are
summarised in Fig. 5 using a 1-year horizon. For 1000
A C
B
Fig. 4 Clinical impact of risk stratification in primary care. Graphs illustrating the impact of introducing NILT into primary care on increasing
identification of advanced fibrosis/ cirrhosis (a), reducing hospital referrals (b) and reducing overall healthcare spend (c), for 1000 NAFLD patients
over 1 year
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patients with NAFLD undergoing PCP assessment for
liver disease, the costs directly associated with NILT
were £10,385 in Scenario 2, £10,632 in scenario 3, £42,
000 in scenario 4 and £43,000 in scenario 5 (incorporat-
ing additional PCP appointments and blood tests).
Compared to SC (scenario 1) which cost £670,504 over
1 year, the incremental reductions in healthcare spending
achieved through use of NILT in each scenario were
£169 K, £152 K, 101 K and 27 K per 1000 patients in 1
year in scenarios 2, 3, 4 and 5 respectively equating to
reductions of 25, 23, 15 and 4%. Using cost-per-case of
advanced fibrosis as a surrogate for cost utility, all sce-
narios were favourable to SC (£25,543.02), with the
model predicting cost-per-case of advanced fibrosis at
£8.932.19, £9083.78, £9487.26 and £10,351.67 in scenar-
ios 2, 3, 4 and 5 respectively over the 1 year timeframe.
From a commissioning perspective, a significant con-
tributor to the immediate cost saving was the reduction
in secondary care referrals. Compared to scenario 1
(£41,300 per 1000 patients over 1 year), cost-savings at-
tributable to reduced specialist referral were £28,895,
£26,216, £23,305 and £11,915 in scenarios 2, 3, 4 and 5
respectively, equating to 70, 63, 56 and 29% reductions.
A budget impact analysis (Table 5) assessed the impact
of introducing the interventions nationally in the UK
NHS system. Assuming the prevalence of NAFLD to be
20% in the UK population of 60 million people and a 5-
year cycle of disease assessment, nationally 2.4 million
Table 4 Base case analysis of introducing FIB-4, ELF and fibroscan into primary care risk stratification pathways compared to
standard of care (scenario 1) after 1 year for 1000 patients with NAFLD
Scenario 2 - FIB-
4/ELF
Scenario 3 - FIB-
4/ TE
Scenario 4 -
SOC + ELF
Scenario 5 -
SOC + TE
Pathway performance: patients referred to specialist (secondary care)
Incremental number of referrals (stratified as ≥F3 fibrosis)
(% increase vs SOC)
−245 (− 70%) − 222 (− 67%) −198 (− 56%) − 101 (25%)
Incremental number of ≥F3 disease referred 30 (53%) 31 (45%) 34 (39%) 36 (25%)
Incremental number of ≤F2 disease referred −275 (−85%) −253 (−78%) − 231 (−71%) −137 (−42%)
Incremental number of cirrhotics referred 1.16 (113%) 1.20 (116%) 1.31 (128%) 1.40 (136%)
Pathway performance: patients remain under primary care management
Incremental number of patient stratified as ≤F2 fibrosis (Primary
care management)
245 (38%) 222 (34%) 198 (30%) 101 (15%)
Incremental number of patients correctly identified as ≤F2 274 (46%) 253 (42%) 231 (38%) 137 (23%)
Incremental number of patients incorrectly identified as ≤F2 −30 (−61%) −31 (−63%) −34 (− 69%) −36 (−74%)
Overall performance of pathways
Sensitivity 0.75 0.76 0.80 0.83
Specificity 0.95 0.92 0.90 0.80
Positive Predictive Value 0.53 0.45 0.39 0.25
Negative Predictive Value 0.98 0.98 0.98 0.98
Positive Likelihood Ratio 14.11 9.96 8.00 4.10
Negative Likelihood ratio 0.27 0.26 0.22 0.21
Impact on end stage liver disease
BCLC Stage 0/A curable HCC
(% of all HCC)
0.06 (36%) 0.06 (38%) 0.07 (41%) 0.08 (44%)
BCLC Stage B-D incurable HCC (% of all HCC) −0.06 (−29%) −0.07 (−30%) −0.07 (−33%) −0.08 (−35%)
Varices detected via surveillance programme (% of all new varices) 0.02 (113%) 0.02 (117%) 0.02 (128%) 0.03 (136%)
Emergency presentation of varices
(% of all new varices)
−0.02 (−30%) − 0.02 (−31%) −0.02 (−34%) −0.03 (−36%)
Mild/Moderate ‘other’ complications < 0.01 (6%) < 0.01 (6%) < 0.01 (7%) < 0.01 (7%)
Severe ‘other’ complication < 0.01 (−9%) < 0.01 (−9%) < 0.01 (−10%) < 0.01 (−10%)
Number of liver transplants (of all cirrhotics known to specialist) 0.02 (32%) 0.02 (33%) 0.03 (36%) 0.03 (39%)
Outcomes
Mortality / 1000 NAFLD patients −0.03 (−0.34%) − 0.03 (− 0.35%) −0.04 (− 0.39%) −0.04 (− 0.41%)
Tabulated analysis of the impact of non-invasive liver fibrosis tests for the management of patients with NAFLD (scenarios 2–5) compared to the standard of care
(scenario 1) in the primary care setting
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people would potentially be risk stratified annually. The
incremental cost to the budget holder of introducing NILT
for fibrosis in NAFLD in primary care would be £24.9M,
£25.5M, £100.8M and £103.2M in scenario’s 2, 3, 4 and 5
respectively. However, this would deliver savings equating
to 23, 21, 14 and 4% reductions in total healthcare expend-
iture for each of the scenarios respectively.
Table 6 summarises the outcomes of introducing non-
invasive liver fibrosis tests in primary care for the base case.
Projected outcomes over a 5 year timeframe
Analyses were performed using a five-year horizon to as-
sess the longer-term outcomes of the pathway (Table 7).
Five years after the introduction of NILT the model
demonstrated clinical benefit, with increases in the detec-
tion of cirrhosis by 107, 111, 123 and 132% in scenarios 2,
3, 4 and 5 respectively equating to an extra 5.69, 5.90, 6.48
and 6.95 cases per 1000 patients tested per year.
Using a discount rate of 3.5%, compared to SC over 5
years incremental savings of £168,449.80, £142,752.51,
£86.604.60 and £20,769.62 were made in scenarios 2, 3,
4, and 5 respectively.
One way sensitivity analyses
We performed a one-way sensitivity analysis on the
base-case scenario using a time-frame of 1 year.
A pathway uptake sensitivity analysis tested assumptions
about the proportion of patients entering the pathway (0–
100%) and confirmed a linear benefit proportional to path-
way uptake and reinforced that any utilisation of the path-
way (i.e. > 0%) would deliver benefit in all scenarios over
the 1-year timeframe.
A clinical effectiveness sensitivity analysis was per-
formed by varying the specificity of SC for the detection
of advanced fibrosis. In the base-case model, a value of
0.65 was assumed (65% specificity for the detection of
advanced fibrosis). To counter the influence of this as-
sumption, around which sparse data are published, it
was varied from 0.00 to 1.00, demonstrating a significant
influence on cost-effectiveness. However, the cost-
benefit was only negated when the specificity of SC for
Fig. 5 Cost impact of risk stratification in primary care. Incremental cost expenditure and savings compared to SOC at different stages of the
management pathway over a 1-year time horizon for 1000 NAFLD patients
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the detection of advanced fibrosis exceeded 0.88, 0.86,
0.80 and 0.68 in scenarios 2, 3, 4 and 5 respectively.
Discussion
Our cost consequence analyses indicate that the use of
NILT to stratify patients with NAFLD in primary care is
clinically effective and cost saving. Utilizing fibroscan
alone was most effective in detecting patients with ad-
vanced fibrosis, whilst employing FIB-4 and ELF deliv-
ered the greatest cost saving.
All of the scenarios using NILT in primary care per-
mitted the earlier identification of advanced fibrosis/
cirrhosis, creating opportunities to modify fibrosis pro-
gression [22, 51] and to start surveillance and treatment
of varices and HCC. Modelling indicated that significant
benefits could accrue from the detection of early stage
curable HCC (stage 0/ A) and non-bleeding varices that
can be treated with beta-blockers and band ligation that
can avert emergency presentations with bleeding varices.
A modest reduction in hospital admissions for other com-
plications of CLD including jaundice, ascites and hepatic
encephalopathy was demonstrated. The relatively limited
impact of current care pathways on mortality, largely at-
tributable to missed or late diagnosis of advanced fibrosis,
Table 5 Budget impact analysis of introducing FIB-4, ELF and fibroscan into primary care risk stratification pathways compared to
standard care after 1 year for a population of 60 million patients
Scenario 2 - FIB-4/
ELF
Scenario 3 - FIB-4/
TE
Scenario 4 - SC +
ELF
Scenario 5 -
SC + TE
Pathway performance:
Incremental number of referrals (stratified as ≥F3 fibrosis) (%
increase vs SOC)
− 587,700 (−70%) − 533,217 (−67%) − 474,000 (−56%) − 242,340 (−25%)
Incremental number of ≥F3 disease referred 71,640 (53%) 74,041 (45%) 81,000 (39%) 86,220 (25%)
Incremental number of ≤F2 disease referred − 659,340 (−85%) − 607,258 (−78%) − 555,021 (−71%) − 328,560 (−42%)
Incremental number of cirrhotics referred 2786 (113%) 2880 (116%) 3153 (128%) 3359 (136%)
Incremental number of patients incorrectly identified as ≤F2 −71,640 (−61%) −74,041 (− 63%) −81,000 (− 69%) −86,220 (− 74%)
IMPACT ON END STAGE LIVER DISEASE
BCLC Stage 0/A curable HCC
(% of all HCC)
121 (36%) 125 (38%) 137 (41%) 146 (44%)
BCLC Stage B-D incurable HCC (% of all HCC) −121 (− 29%) − 125 (− 30%) −137 (− 33%) − 146 (− 35%)
Varices detected via surveillance programme (% of all new varices) 50 (113%) 51 (117%) 57 (128%) 60 (136%)
Emergency presentation of varices
(% of all new varices)
−50 (− 30%) −51 (− 31%) −57 (− 34%) −60 (− 36%)
Mild/Moderate ‘other’ complications 5 (6%) 5 (6%) 6 (7%) < 6 (7%)
Severe ‘other’ complication requiring hospital admission −5 (− 9%) − 5 (− 9%) − 6 (− 10%) −6 (− 10%)
Outcomes
Mortality / 1000 NAFLD patients −67 (− 0.34%) −69 (− 0.35%) −76 (− 0.39%) −81 (− 0.41%)
Budget
Cost of tests £24.9 M £25.5 £100.8 £103.2 M
Total expenditure -£406 M (−23%) -£364 M (−21%) -£243 M (−14%) -£65 M (− 4%)
Tabulated analysis of the impact of non-invasive liver fibrosis tests for the management of patients with NAFLD (scenarios 2–5) compared to the standard of care
(scenario 1) in the primary care setting for a population of 60 million patients with 20% NAFLD prevelance risk stratified on a 5 year cycle
Table 6 Summary of outcomes resulting from introducing non-invasive liver fibrosis tests in primary care (per 1000 NAFLD patients
over 1 years)
Scenario 1
Standard Care
Scenario 2
FIB 4 +/− ELF
Scenario 3
FIB 4 +/− TE
Scenario 4
ELF
Scenario 5
TE
Total Referrals avoided (vs. SOC) – 245 234 198 150
Cases F3/F4 detected 26.3 56.1 57.1 60.0 62.2
Cases Cirrhosis detected 5.3 11.0 11.2 11.8 12.3
Cases Cirrhosis missed 11.3 5.5 5.3 4.7 4.2
Cost saving (vs. SOC) – - £169,408 - £151,816 - £101,268 - £26,889
Cost per ≥ F3 detected £25,543 £8932 £9083 £9487 £10,351
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highlights the need for new approaches to diagnosis and
treatment to prevent NAFLD progression.
Of interest to commissioners, the implementation of
NILT in primary care offers the potential to reduce the
total number of referrals, and in particular the unneces-
sary referral of patients who have minimal fibrosis. Over a
1-year horizon, there was a reduction in total referrals of
70, 63, 56 and 29% in scenarios 2, 3, 4 and 5 respectively,
with an 85, 78, 71 and 42% reduction in referrals of pa-
tients with non-advanced disease. Real-world data from a
secondary care hepatology service found that 66% of re-
ferred patients had a baseline FIB-4 score < 1.30 indicating
that these patients had a low risk of advanced fibrosis and
could have avoided referral [13]. This group of patients
represents an inefficient use of resources, adding pressure
to overstretched outpatient specialist services and PCP
healthcare budgets [52]. Introduction of the use of NILT
in primary care would deliver immediate reductions in ex-
penditure through avoidance of unnecessary referrals, un-
like the cost-benefits associated with improved outcomes
attributable to earlier diagnosis that accrue much later.
All scenarios were cost saving. The cost of detecting a
case of advanced fibrosis using SC was £49,917.83 in
scenario. This compared to £19,360.75 in scenario 2,
£19,448.49 in scenario 3, £19,487.75 in scenario 4 and
£20,451.35 in scenario 5. Healthcare budgets were re-
duced by 17, 15, 11 and 3% in scenarios 2, 3, 4 and 5 re-
spectively, attributable to the reduction in costs
associated with end stage liver disease and improved re-
source utilisation. The budget decrease in scenario 5 was
modest as it was assumed all patients who failed fibros-
can (5% of cohort) were referred to specialists.
In this analysis, we explored the impact of the use of
FIB-4 and ELF to replicate a primary care pathway intro-
duced in north London. This combination of tests was
optimal for the stratification of patients in a hospital
based population [53] and has subsequently been shown
to be clinically effective [13] when applied in primary
care where the proportion of cases of advanced fibrosis
amongst cases of NAFLD is smaller.
There are limitations to the model. The model was popu-
lated with the best available published evidence. A lack of
high quality data for some variables was remedied with ex-
pert opinion. The measures of performance for FIB-4, ELF
and fibroscan were drawn from validations in hospital co-
horts, but these estimates may be inappropriately high for
primary care populations in which the prevalence of fibrosis
is likely to be lower (spectrum bias) [54, 55]. The model as-
sumes that use of ELF and fibroscan as second-tier tests
has the same performance characteristics as a first-tier test.
This may under-estimate the performance of the pathway.
Additionally, the model was limited to FIB-4, ELF and
fibroscan. Local PCP focus groups supported by consul-
tants in Public Health, formed to aide Camden and Isling-
ton pathway development, outlined the practical need for
simplicity, giving FIB-4 an advantage over the NAFLD-
fibrosis score, which the PCP considered to be more chal-
lenging to obtain such as BMI, or associated with uncer-
tainty about case definition such as diabetes. The model
examines fibrosis, but not NASH, and so may underesti-
mate disease progression. Other sources of error include
analytical performance. We assumed a 5% failure rate for
fibroscan but higher rates have been reported [47], whilst
serum tests can be influenced by comorbidities. For the
Table 7 Projected clinical outcomes and costs of the scenarios projected over 1 year and 5 years
Scenario 1- SC Scenario 2 - FIB-4/
ELF
Scenario 3 - FIB-4/
TE
Scenario 4 - SC +
ELF
Scenario 5 - SC +
TE
1 year 5 years 1 year 5 years 1 year 5 years 1 Year 5 years 1 year 5 years
Total number of cirrhotics entered into
specialist services (out of all cirrhotics)
1.03
(34%)
5.28
(32%)
2.19
(74%)
10.97
(66%)
2.23
(75%)
11.17
(68%)
2.34
(79%)
11.75
(71%)
2.43
(82%)
12.23
(74%)
Total number of cirrhotics not known to
specialist services (out of all cirrhotics)
1.96
(66%)
11.278
(68%)
0.78
(26%)
5.53
(34%)
0.74
(25%)
5.41
(32%)
0.63
(21%)
4.73
(29%)
0.54
(18%)
4.24
(26%)
Early stage complication (stage 0/A HCC,
non-bleeding varices, mild ascites etc)
(% of all complications)
Cost
0.22
(42%)
£3.0 K
3.52
(39%)
£31.1 K
0.31
(57%)
£4.1 K
4.62
(52%)
£41.2 K
0.31
(58%)
£4.1 K
4.66
(52%)
£41.5 K
0.32
(60%)
£4.3 K
4.77
(54%)
£42.6 K
0.33
(61%)
£4.3 K
4.87
(55%)
£43.4 K
Late stage complication (stage B-D HCC,
bleeding varices, severe ascites etc)
(% of all complications)
Cost
0.32
(58%)
£12.9 K
5.44
(61%)
£141 K
0.23
(43%)
£9.2 K
4.3 (48%)
£108 K
0.23
(42%)
9.1 K
4.26
(48%)
£107 K
0.22
(40%)
£8.8 K
4.14
(46%)
£103 K
0.21
(39%)
£8.4 K
4.05
(45%)
£101 K
Liver transplant
Cost
0.07 £5.9
K
1.05
£89.5 K
0.10
£7.9 K
1.16
£98.9 K
0.10
£8.0 K
1.16
£99.3 K
0.10
£8.2 K
1.17100.2
K
0.10
£8.3 K
1.18
£101 K
Mortality (%) 9.87
0.99%
28.56
2.86%
9.84
0.98%
28.18
2.82%
9.83
0.98%
28.17
2.82%
9.83
0.98%
28.13
2.81%
9.83
0.98%
28.10
2.81%
Total cost/1000 NAFLD patients 638 K 1.1 M 502 K 946 K 522 K 971 K 570 K 1.0 M 647 K 1.1 M
Cost/advanced fibrotic detected 25.7 K 49.9 K 9.0 K 19.4 K 9.1 K 19.4 K 9.5 K 19.5 K 10.4 K 20.5 K
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purposes of the model, liver biopsy was considered the ref-
erence test for liver fibrosis. Given the inherent inaccuracies
associated with liver biopsy [56], this may have over-
estimated the performance of liver biopsy. The cost esti-
mate of liver biopsy incorporated procedural elements but
not those associated with complications of the procedure.
This approach may underestimate the true cost associated
with liver biopsy. The clinical- and cost- efficiency of all
scenarios are highly favourable, but may not reflect real-life
outcomes. Not all patients with NAFLD consult their PCP,
and pathway uptake by health professionals is variable. The
base case is a 50-year-old man with abnormal transami-
nases, reflecting a screening strategy identified by the Cam-
den and Islington steering committee as practical in real-
life primary care practice. However this approach will miss
cases of NAFLD with advanced fibrosis but normal LFTs. A
screen-all strategy is likely to be clinically optimal, as pa-
tients with NAFLD and normal transaminases are at risk of
significant fibrosis. The costing in the model is comprehen-
sive, assuming full adherence to guidelines and protocols
and thereby potentially overestimating the cost of care. We
employed a probabilistic decision model as our main eco-
nomic focus was on the payer perspective rather than a
population health perspective, where alternative cost-
effectiveness approaches using quality of life data and Mar-
kov simulations would be desirable. The lack of beta or tri-
angular distributions and true probability sensitivity
analysis limits the model. The model lacks cost/ QALY data
and relies on descriptive measures including cost per case
of advanced fibrosis detected. These outcome measures
have no standard comparator limiting the current model.
These shortcomings will be addressed in future work.
NAFLD should be considered as the hepatic manifest-
ation of a multisystem disorder associated with wide-
spread morbidity including cardiovascular disease,
diabetes, hyperlipidaemia and cancer. While a fully com-
prehensive health economic model would need to take
these morbidities into consideration we chose to focus
on liver disease. Accommodating all NAFLD associated
morbidities, their evaluation and management was be-
yond the scope of this study.
This study has several strengths. A comprehensive lit-
erature review was undertaken to identify estimates for
clinical parameters, transition rates and costs. The study
adds to the current body of evidence and our conclu-
sions are similar to other health economic analyses [57].
A Health Technology Assessment undertaken for the
National Institute for Health Research [19] concluded
that use of NILT was more cost-effective than liver bi-
opsy in detecting cases of advanced fibrosis. Tapper et
al. [58] demonstrated that the use of the NAFLD fibrosis
score and fibroscan in primary care yielded cost-effective
results. Robust data are lacking regarding the perform-
ance of PCP’s in the identification of patients with
advanced liver disease. Additionally, there is no pub-
lished randomised controlled trial exploring the per-
formance of NILT in primary care. Whilst limiting the
model, the information provided by the analysis may be
supplemented with the results from real-life pilot studies
in due course. Harman et al. [59] have demonstrated the
use of fibroscan in patients with risk factors for CLD, in-
cluding diabetes, obesity and alcohol excess can increase
detection of cirrhosis by 140%, similar to the modelling
results in scenario 5 (132%). Our group has evaluated
the pathway employing FIB-4 and ELF (Scenario 2) [13].
Conclusions
This study demonstrates that the introduction of NILT in
primary care has the potential to increase the detection of
cases of NAFLD with advanced fibrosis and cirrhosis, re-
duce unnecessary referrals to secondary care of patients at
low risk of liver disease and to deliver immediate and sus-
tained significant cost savings. The model provides com-
pelling evidence for clinicians, commissioners and policy
makers to consider the formal introduction of non-
invasive liver fibrosis testing in primary care, in line with
other central policy statements [4, 60, 61].
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